Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

The war on kush: The synthetic drug sweeping through parts of Africa

A new report by an anti-transnational crime group has identified the core chemical components of kush, a synthetic drug that has swept through Sierra Leone and the region in the past few years.

The Independent UK

The Latest: Musk renews threat to fire federal workers despite pushback from various agencies

Elon Musk is vowing yet again to fire any federal workers who don’t respond to an email asking them to list five things they accomplished last week

The Independent UK

Biological E Limited partners with Bavarian Nordic to increase global access to Chikungunya Vaccine

This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage. Read further on Dynamite News:

Dynamite News

From analysis to the latest developments in health,
read the most diverse news in one place.

Why has Unilever CEO Hein Schumacher stepped down and who is replacing him?

Mr Schumacher was named CEO in 2023 following the retirement of Alan Jope but has now stepped down in a surprise move

Evening Standard

3 Pharmaceutical Stocks With Blockbuster Drug Potential

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

StockNews.com

Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs

Argenx recently hit an all-time high ahead of fourth-quarter earnings. Shares are in a flat base with a buy point of 678.21.

Investors Business Daily

Profit Machine Penumbra Surges On Solid Fourth-Quarter Beat, But Guidance Lags

Penumbra stock gapped up Wednesday after the medtech company beat fourth-quarter expectations, though its revenue guidance came in shy.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why Medtronic Just Undercut Its Buy Zone With A 7% Drop

Medtronic stock skidded Tuesday after the medtech giant missed sales expectations, though profit came in well ahead of forecasts.

Investors Business Daily

Moderna Stock Reverses As CEO Stephane Bancel Deflects Concerns Over RFK Jr.

Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

Investors Business Daily

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investors Business Daily

Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat

Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.

Investors Business Daily

Gilead Hits Buy Zone After Obliterating Fourth-Quarter Expectations

Gilead stock surged to a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat profit outlook.

Investors Business Daily

Biohaven Just Hurdled An FDA Setback — And Its Moving Lines

Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.

Investors Business Daily

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

Salon

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

The Guardian - UK

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

Investors Business Daily

IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad

Hims stock surged Friday after facing backlash over its provocative Super Bowl ad.

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Investors Business Daily

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares quadruple last year.

The Independent UK

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

StockNews.com

Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication towards being a top contender in the highly contested biotech market. So, should investors looking to capitalize on the industry’s prospects consider investing in HRMY? Read more….

The Guardian - UK

AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project

As drugmaker reports 38% jump in profits, CEO denies tension with UK government after Speke plant decision

The Guardian - UK

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

The Guardian - UK

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

1 2 3 4 5

People

Lars Fruergaard Jørgensen

12 stories

Carl Cashman

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.